


## What is immunotherapy?

Immunotherapy is a therapeutic approach which makes use of the extraordinary potential of the individual immune system to cure diseases.

Although the first discoveries in this field date back to more than 100 years ago, immunotherapy currently remains a health care top trend. Over the last years, the positive outcome of many immunotherapy-based clinical studies convincingly demonstrated that the immune system can be effectively used as weapon against cancer.

Up to now, several immunotherapeutic strategies have been developed. They can be classified in those targeting cancer cells and those priming the immune system against cancer and also, increasingly, against other diseases.



Cancer immunotherapies (modified from Sathyanarayanan and Neelapu, 2015)

## Contact

Bio<sup>M</sup> Biotech Cluster Development GmbH  
Am Klopferspitz 19a | 82152 Martinsried, München

Dr. Alessandra Pasquarella  
Project manager ImmPact  
E-mail: pasquarella@bio-m.org  
Phone: (+49) (0)89 / 89 96 79 27

accelerating biomedical innovation



The network for innovative immunotherapies



ImmPact Bavaria is financed by ZIM (Zentrales Innovationsprogramm Mittelstand), a German funding program which supports small and medium-sized enterprises (SMEs) through the establishment of cooperative networks.



# ImmPact Bavaria

ImmPact Bavaria is a cooperative network which gathers immuno-oncology/ immunotherapy/ immune intervention experts in order to promote and develop innovative healthcare strategies.

Today, ImmPact Bavaria consists of 11 partner companies which are, together with Bio<sup>M</sup>, the founders of the network.

The very diverse and non-competitive immunotherapeutic and technological approaches developed by each company provide an excellent knowledge base to initiate successful collaborative actions.

ImmPact Bavaria is an initiative of Bio<sup>M</sup>.

## Why do we need an innovative immunotherapy network?

Although the efficacy of immunotherapy against cancer is undeniable, many medical needs remain still unmet.


This is due to

- the huge complexity of cancer biology,
- the incomplete understanding of immune mechanisms.

The enormous explorative potential of the immune system – together with the intricate nature of cancer – mark immunotherapy as a very promising and complicated field at the same time. Therefore the joint effort of several experts is a key requirement to develop efficient, innovative and trustable immunotherapeutic protocols.

## Technological goals

- Combination of immunotherapeutic approaches
- Immunomonitoring
- Co-discovery of new immunotherapeutic solutions
- Efficient and cost-effective production of cell-based immunotherapies



## Conceptual goals

- Establishing a solid network mindset and identity
- Building a robust and enduring dialogue between academia and industry
- Maximizing the exchange of know-how and knowledge
- Generating platforms, infrastructures and events to promote partnership activities (e.g. databases, workshops, facilities, conferences)
- Expanding the network Germany-wide or even Europe-wide
- Approaching the international pharma industry

## ImmPact Bavaria: Ongoing work

Although ImmPact Bavaria is a brand-new project, many ideas and purposes have already entered their concrete realization phase.

Currently, we are

- expanding the network to academic research institutes and specialized clinics in Bavaria (FAU<sup>1</sup>, JMU<sup>2</sup>, LMU<sup>3</sup>, TUM<sup>4</sup>, UR<sup>5</sup>),
- generating marketing material (website and flyers) to attract investors and partners,
- organizing get-togethers of the partners in a regular way to initiate productive collaborations,
- planning meetings between industry and academia,
- starting to examine the first project proposals,
- analyzing profiles and needs of each partner company to ensure productive partnerships,
- identifying new therapeutic trends.

1: Friedrich-Alexander-Universität Erlangen-Nürnberg 2: Julius-Maximilians-Universität Würzburg 3: Ludwig-Maximilians-Universität München

4: Technische Universität München 5: Universität Regensburg

Let's take immunotherapy to the next level!  
Join us!

